risperidone has been researched along with Acute Edematous Pancreatitis in 9 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our previous study suggested that a combination of ulinastatin and risperidone reduced post-ERCP pancreatitis (PEP) compared with ulinastatin alone." | 9.17 | Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial. ( Akiyama, D; Arizumi, T; Hamada, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Nakajima, K; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Tsujino, T; Uchino, R; Yagioka, H; Yamamoto, N; Yanagihara, Y, 2013) |
| " Six patients in the risperidone + ulinastatin group and ten patients in the ulinastatin group developed pancreatitis (5." | 9.17 | The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial. ( Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yamamoto, N; Yashima, Y, 2013) |
| " Here, authors report on an interesting case of risperidone-induced pancreatitis in a child with ADHD comorbid with conduct disorder." | 8.12 | Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. ( Alamiri, B; Naguy, A; Roshdy, R, 2022) |
| "In a previous article, we showed that a potent serotonin-, 5-hydroxytryptamine-2A (5-HT(2A)) antagonist, risperidone, ameliorated cerulein-induced edematous pancreatitis in mice." | 7.75 | Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. ( Hamada, K; Isayama, H; Kanazashi, S; Takeuchi, K; Yamaguchi, I; Yoshida, M, 2009) |
| "Our previous study suggested that a combination of ulinastatin and risperidone reduced post-ERCP pancreatitis (PEP) compared with ulinastatin alone." | 5.17 | Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial. ( Akiyama, D; Arizumi, T; Hamada, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Nakajima, K; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Tsujino, T; Uchino, R; Yagioka, H; Yamamoto, N; Yanagihara, Y, 2013) |
| " Six patients in the risperidone + ulinastatin group and ten patients in the ulinastatin group developed pancreatitis (5." | 5.17 | The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial. ( Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yamamoto, N; Yashima, Y, 2013) |
| " Here, authors report on an interesting case of risperidone-induced pancreatitis in a child with ADHD comorbid with conduct disorder." | 4.12 | Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. ( Alamiri, B; Naguy, A; Roshdy, R, 2022) |
| "In a previous article, we showed that a potent serotonin-, 5-hydroxytryptamine-2A (5-HT(2A)) antagonist, risperidone, ameliorated cerulein-induced edematous pancreatitis in mice." | 3.75 | Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. ( Hamada, K; Isayama, H; Kanazashi, S; Takeuchi, K; Yamaguchi, I; Yoshida, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Naguy, A | 1 |
| Roshdy, R | 1 |
| Alamiri, B | 1 |
| Uchino, R | 1 |
| Isayama, H | 3 |
| Tsujino, T | 2 |
| Sasahira, N | 2 |
| Ito, Y | 2 |
| Matsubara, S | 2 |
| Takahara, N | 1 |
| Arizumi, T | 2 |
| Toda, N | 2 |
| Mohri, D | 1 |
| Togawa, O | 2 |
| Yagioka, H | 2 |
| Yanagihara, Y | 1 |
| Nakajima, K | 1 |
| Akiyama, D | 1 |
| Hamada, T | 1 |
| Miyabayashi, K | 1 |
| Mizuno, S | 2 |
| Kawakubo, K | 1 |
| Kogure, H | 2 |
| Sasaki, T | 2 |
| Yamamoto, N | 2 |
| Nakai, Y | 2 |
| Hirano, K | 2 |
| Tada, M | 2 |
| Koike, K | 2 |
| Enns, R | 1 |
| Lee, S | 1 |
| Yamaguchi, I | 1 |
| Hamada, K | 1 |
| Yoshida, M | 1 |
| Kanazashi, S | 1 |
| Takeuchi, K | 1 |
| Ghio, L | 1 |
| Fornaro, G | 1 |
| Rossi, P | 1 |
| Yamamoto, K | 1 |
| Yashima, Y | 1 |
| Hanft, A | 1 |
| Bourgeois, J | 1 |
| Berent, I | 1 |
| Carabeth, J | 1 |
| Cordero, MM | 1 |
| Cordero, R | 1 |
| Sugerman, B | 1 |
| Robinson, D | 1 |
| Cordeiro, Q | 1 |
| Elkis, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000459] | Phase 3 | 0 participants | Interventional | 1986-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for risperidone and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial.
Topics: Adult; Aged; Ampulla of Vater; Amylases; Bile Ducts, Intrahepatic; C-Reactive Protein; Cholangiopanc | 2013 |
The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.
Topics: Administration, Oral; Adult; Aged; Cholangiopancreatography, Endoscopic Retrograde; Drug Therapy, Co | 2013 |
7 other studies available for risperidone and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD.
Topics: Acute Disease; Attention Deficit Disorder with Hyperactivity; Child; Conduct Disorder; Humans; Pancr | 2022 |
Preventing post-ERCP pancreatitis.
Topics: Ampulla of Vater; Bile Ducts, Intrahepatic; Cholangiopancreatography, Endoscopic Retrograde; Female; | 2013 |
Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Anti-Inflammatory Agents; Choline Deficiency; Ethionine; Female; I | 2009 |
Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report.
Topics: Antipsychotic Agents; Female; Humans; Hyperamylasemia; Injections, Intramuscular; Intubation, Gastro | 2009 |
Risperidone and pancreatitis.
Topics: Antipsychotic Agents; Child; Humans; Male; Pancreatitis; Risperidone | 2004 |
Pancreatitis associated with risperidone treatment?
Topics: Acute Disease; Adult; Humans; Male; Pancreatitis; Risperidone; Schizophrenia | 1997 |
Pancreatitis and cholestatic hepatitis induced by risperidone.
Topics: Adult; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Cholestasis; Humans; Male; Panc | 2001 |